ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.

Prof Philipp Lurz (Leipzig Heart Institute, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation severity influences outcomes following transcatheter tricuspid valve replacement with the Edwards EVOQUE system.

This pivotal randomized controlled trial enrolled over 400 patients with at least severe tricuspid regurgitation across multiple centers, who were randomized 2:1 to recieve either TTVR or control. The primary endpoint was a win ratio analysis including both hard clinical endpoints, and quality of life at one year.

Findings showed that the study clearly met its primary endpoint with a WIN ratio of 2.02, mainly driven by improvements in quality of life (6 Minute Walking Distance, NYHA Improvement and KCCQ-OS improvement), but also reduced rates of all-cause mortality and TV intervention.

Interview Questions:

1. How does baseline TR severity impact current treatment descisions?
2. Could you remind us of the study design and patient population?
3. What were the key findings?
4. What are the clinical implications of these findings for patient selection and procedural planning in TTVR?
5. How should these findings influence approaches to timing of intervention in patients with progressive TR?
6. What are your key takeway messages?

Recorded on-site at ESC Congress 2025, Madrid.

Editors: Jordan Rance, Yazmin Sadik.
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.